Dr Nimesh Desai (Hospital of the University of Pennsylvania, USA) presented the results of the STS/ACC TVT Registry. The purpose of the study was to determine whether site-level variation exists in TAVR quality of care in the USA using a novel, patient-centric, 30-day, composite-outcome measure, comparing each hospital to the national average. The patient cohort consisted of patients who underwent transfemoral TAVR for symptomatic aortic stenosis between 1 January 2015 and 31 December 2017. Data from hospitals with >10% missing data for the outcome variable and other key study variables was excluded. A ranked composite outcome selection was developed consisting of periprocedural complications determined by their adjusted association with 1-year mortality and patient quality of life, based on the Kansas City Cardiomyopathy Questionnaire (KCCQ); and any outcome with significant hazard ratio was maintained. When ranking the endpoints, the outcome with the highest rank was assigned if patients had more than 1 outcome. The overall model was a hierarchical, multi-category, logistic regression model that estimates a set of hospital-specific odds ratios. Site difference was defined as a random patient doing worse at an average hospital and a random patient doing better at an average hospital.
It emerged that 11% of the 301 included sites performed worse than expected, 80% performed as expected, and 8% better than expected. The reliability of the model was tested, and it showed moderate-to-high reliability even when including lower-volume programmes. However, the researchers acknowledged that the analysis had its limitations including that it did not examine the quality of care of patients who underwent TAVR using non-femoral access as well as missing baseline KCCQ-12 and gait speed data, which limited the number of sites included in this analysis. The steering committee of the STS/ACC TVT registry commissioned the composite metric, said Dr Desai, and it has already been approved for use.
- Desai N, et al. Abstract 405-12. ACC/WCC 28-30 March 2020.
Posted on
Previous Article
« TAVR versus surgery in older patients Next Article
Tiragolumab and atezolizumab: ORR in NSCLC »
« TAVR versus surgery in older patients Next Article
Tiragolumab and atezolizumab: ORR in NSCLC »
Table of Contents: ACC/WCC 2020
Featured articles
Heart Failure and Cardiomyopathies
Mavacamten shows promising results in non-obstructive hypertrophic cardiomyopathy
Vericiguat shows beneficial effects in a very high-risk HF population
No role for sodium nitrite in out-of-hospital cardiac arrest
Vascular Medicine and Thromboembolism
Rivaroxaban and aspirin effective and safe for PAD patients
TAILOR-PCI misses endpoint but still provides valuable insights
Edoxaban: alternative to warfarin after surgical aortic or mitral valve procedures?
Bleeding reduction post-TAVI with OAC alone vs OAC + clopidogrel
Apixaban offers new perspective for cancer patients in need of anticoagulation
Rivaroxaban superior to enoxaparin in preventing VTE in non-major orthopaedic surgery
Interventional Cardiology
TAVR safe and effective in low-risk bicuspid aortic stenosis patients
TAVR model reveals differences in hospital outcomes
2-year results show non-significant outcomes TAVR vs surgery in severe aortic stenosis
Renal denervation better than sham for blood pressure
Infusion of ethanol in the vein of Marshall for persistent AF
Atrial Fibrillation/Acute Coronary Syndrome
Fewer adverse events with ticagrelor monotherapy after 3 months DAPT
TWILIGHT sub-study: same outcomes for diabetes patients
TWILIGHT sub-study: complex PCI patients
LAAO Watchman registry data positive
Apixaban in AF patients with recent ACS/PCI: Drop aspirin after 30 days
Genetics and Prevention
Homozygous FH responds to alirocumab
Evinacumab significantly reduces LDL-C in homozygous FH patients
Higher serum levels of eicosapentaenoic acid correlate with reduced CV events
Quit smoking: vaping + counselling helps
Related Articles
September 7, 2020
Rivaroxaban and aspirin effective and safe for PAD patients
September 7, 2020
Bleeding reduction post-TAVI with OAC alone vs OAC + clopidogrel
September 8, 2020
Radial artery best for second bypass
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com